BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

...internally developed product to gain the designation in China. Merck buys rest of Lumos voucher Lumos Pharma Inc....
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

...Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse...
...with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
...which will retain Lumos’ name, plans to start a Phase IIb trial in mid-2020 of Lumos'...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...portfolio also includes cancer companies Iterion Therapeutics and Molecular Therapeutics Inc. and rare disease play Lumos Pharma Inc....
BioCentury | Apr 21, 2016
Company News

Management tracks

...Mauro as CMO. He was EVP and CMO at Advaxis Inc. (NASDAQ:ADXS). Rare disease company Lumos Pharma Inc....
BioCentury | Apr 14, 2016
Company News

Management tracks

...He was SVP and head of worldwide medical at Biogen Inc. (NASDAQ:BIIB). Orphan disease company Lumos Pharma Inc....
BioCentury | Apr 11, 2016
Financial News

Lumos completes venture financing

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Date completed: 2016-04-06 Type: Venture financing Raised: $34 million Investors: Deerfield Management; Clarus Ventures; Roche Venture Fund; New Enterprise Associates; Sante Ventures LLC; UCB Group WIR Staff...
BioCentury | Apr 7, 2016
Financial News

Orphan play Lumos raises $34M

...also participated, as did existing investors New Enterprise Associates, Sante Ventures and UCB Group (Euronext:UCB). Lumos'...
...but cannot actively transport it across the blood-brain barrier. President and CEO Rick Hawkins said Lumos...
...trial in healthy volunteers and evaluate LUM-001 in a cohort of about 10 CTD patients. Lumos...
BioCentury | Apr 14, 2014
Clinical News

Recombinant human nerve growth factor: Phase Ib/II started

...Dompe began the 24-week, double-blind, vehicle-controlled, Italian Phase Ib/II Lumos trial to evaluate 60 and 180...
BioCentury | Feb 10, 2014
Company News

Lumos board of directors update

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Appointed: Kevin Lalande, managing director at Sante Ventures; and Ed Mathers, partner at New Enterprise Associates WIR Staff...
BioCentury | Feb 10, 2014
Financial News

Lumos completes venture financing

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Date completed: 2/4/14 Type: Venture financing Raised: $14 million Investors: Sante Ventures; New Enterprise Associates WIR Staff...
Items per page:
1 - 10 of 15
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

...internally developed product to gain the designation in China. Merck buys rest of Lumos voucher Lumos Pharma Inc....
BioCentury | Sep 30, 2019
Company News

Sept. 30 Company Quick Takes: Lumos-NewLink, Simcere-JW, Ocugen-CanSino, Chamishi’s launch, and AbbVie-Allergan

...Lumos finds public pat h Rare disease company Lumos Pharma Inc. plans to go public via a reverse...
...with NewLink Genetics Corp. (NASDAQ:NLNK). Set to own about 50% of the combined company are Lumos’...
...which will retain Lumos’ name, plans to start a Phase IIb trial in mid-2020 of Lumos'...
BioCentury | May 30, 2019
Finance

Santé seeks bigger stakes with $250M new fund

...portfolio also includes cancer companies Iterion Therapeutics and Molecular Therapeutics Inc. and rare disease play Lumos Pharma Inc....
BioCentury | Apr 21, 2016
Company News

Management tracks

...Mauro as CMO. He was EVP and CMO at Advaxis Inc. (NASDAQ:ADXS). Rare disease company Lumos Pharma Inc....
BioCentury | Apr 14, 2016
Company News

Management tracks

...He was SVP and head of worldwide medical at Biogen Inc. (NASDAQ:BIIB). Orphan disease company Lumos Pharma Inc....
BioCentury | Apr 11, 2016
Financial News

Lumos completes venture financing

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Date completed: 2016-04-06 Type: Venture financing Raised: $34 million Investors: Deerfield Management; Clarus Ventures; Roche Venture Fund; New Enterprise Associates; Sante Ventures LLC; UCB Group WIR Staff...
BioCentury | Apr 7, 2016
Financial News

Orphan play Lumos raises $34M

...also participated, as did existing investors New Enterprise Associates, Sante Ventures and UCB Group (Euronext:UCB). Lumos'...
...but cannot actively transport it across the blood-brain barrier. President and CEO Rick Hawkins said Lumos...
...trial in healthy volunteers and evaluate LUM-001 in a cohort of about 10 CTD patients. Lumos...
BioCentury | Apr 14, 2014
Clinical News

Recombinant human nerve growth factor: Phase Ib/II started

...Dompe began the 24-week, double-blind, vehicle-controlled, Italian Phase Ib/II Lumos trial to evaluate 60 and 180...
BioCentury | Feb 10, 2014
Company News

Lumos board of directors update

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Appointed: Kevin Lalande, managing director at Sante Ventures; and Ed Mathers, partner at New Enterprise Associates WIR Staff...
BioCentury | Feb 10, 2014
Financial News

Lumos completes venture financing

Lumos Pharma Inc. , Austin, Texas Business: Endocrine/Metabolic Date completed: 2/4/14 Type: Venture financing Raised: $14 million Investors: Sante Ventures; New Enterprise Associates WIR Staff...
Items per page:
1 - 10 of 15